Sanofi’s Tzield Gains FDA Approval in Stage 3 Type 1 Diabetes
PARIS, France, June 13, 2026 Sanofi has achieved a major breakthrough in diabetes care after the U.S. Food and...
Type 1 Diabetes
Advertisement
Syntax Bio Teams Up with Mayo Clinic to Advance Diabetes Treatment
CHICAGO, June 10, 2026 Syntax Bio announced a research and development collaboration with Mayo Clinic to accelerate the development...
Tandem Diabetes Care Expands CE Mark for AID Systems
SAN DIEGO, June 5, 2026 Tandem Diabetes Care announced that its t:slim X2 and Tandem Mobi automated insulin delivery...
Cirius Therapeutics Highlights CIR-0602K as Promising New Therapy for Type 2 Diabetes
GRAND RAPIDS, Mich., June 1, 2026 Cirius Therapeutics has announced the presentation of new clinical data supporting CIR-0602K, its...
MannKind Gains FDA Approval for Afrezza in Pediatric Diabetes
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 MannKind Corporation announced that the U.S. Food and Drug Administration...
Advertisements
Century Therapeutics Highlights CNTY-813 Data at ADA
PHILADELPHIA, Pennsylvania, April 2026 Century Therapeutics announced that its investigational program CNTY-813 has been selected for oral presentation at...
Mozart Therapeutics Shows Disease-Modifying Potential in Phase 1 Trial
Seattle, Washington, USA & Brisbane, Australia – April 23, 2026 Mozart Therapeutics announced positive interim Phase 1b clinical data...
Sanofi Secures FDA Approval for Tzield in Young T1D
Paris, France – April 22, 2026 In a landmark advancement for pediatric endocrinology, Sanofi has secured U.S. FDA approval...
vTv Therapeutics Strengthens Balance Sheet for Phase 3
HIGH POINT, N.C., November 6, 2025 — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company developing innovative oral...
Advertisement
